Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report
Introduction: Multiple Myeloma (MM) is currently an incurable disease, with constant relapses and the need for multiple lines of treatment. Immune therapies, which include bispecific antibodies such as elranatamab, are a new option for the treatment of patients with relapsed/refractory MM (R/R MM),...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Inglés |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2026
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/49234 |
| Aporte de: |
| id |
I10-R327-article-49234 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Inglés |
| format |
Artículo revista |
| topic |
multiple myeloma tumor lysis syndrome bispecific antibodies Multiple Myeloma Tumor Lysis Syndrome Immunotherapy Elranatamab mieloma múltiple síndrome de lisis tumoral anticuerpos biespecíficos Mieloma Múltiple Síndrome de lísis tumoral Inmunoterapia Elranatamab mieloma múltiplo síndrome de lise tumoral anticorpos biespecíficos Mieloma Múltiplo Síndrome de Lise Tumoral Imunoterapia Elranatamab |
| spellingShingle |
multiple myeloma tumor lysis syndrome bispecific antibodies Multiple Myeloma Tumor Lysis Syndrome Immunotherapy Elranatamab mieloma múltiple síndrome de lisis tumoral anticuerpos biespecíficos Mieloma Múltiple Síndrome de lísis tumoral Inmunoterapia Elranatamab mieloma múltiplo síndrome de lise tumoral anticorpos biespecíficos Mieloma Múltiplo Síndrome de Lise Tumoral Imunoterapia Elranatamab Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report |
| topic_facet |
multiple myeloma tumor lysis syndrome bispecific antibodies Multiple Myeloma Tumor Lysis Syndrome Immunotherapy Elranatamab mieloma múltiple síndrome de lisis tumoral anticuerpos biespecíficos Mieloma Múltiple Síndrome de lísis tumoral Inmunoterapia Elranatamab mieloma múltiplo síndrome de lise tumoral anticorpos biespecíficos Mieloma Múltiplo Síndrome de Lise Tumoral Imunoterapia Elranatamab |
| author |
Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa |
| author_facet |
Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa |
| author_sort |
Milanesio, Martín |
| title |
Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report |
| title_short |
Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report |
| title_full |
Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report |
| title_fullStr |
Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report |
| title_full_unstemmed |
Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report |
| title_sort |
clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report |
| description |
Introduction: Multiple Myeloma (MM) is currently an incurable disease, with constant relapses and the need for multiple lines of treatment. Immune therapies, which include bispecific antibodies such as elranatamab, are a new option for the treatment of patients with relapsed/refractory MM (R/R MM), with high effectiveness, but not free of adverse reactions. Tumor lysis syndrome (TLS) is a rare complication of MM treatment and has not been reported after application of elranatamab.
Case Presentation: We report the case of a man with R/R MM who presented TLS after application of the first dose of elranatamab. The TLS resolved after supportive measures without subsequent recurrence.
Conclusion: TLS is an uncommon complication of MM treatment and could be triggered by bispecific antibodies. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2026 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/49234 |
| work_keys_str_mv |
AT milanesiomartin clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT olmedojulieta clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT caeirogaston clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT basquieraanalisa clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT milanesiomartin clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT olmedojulieta clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT caeirogaston clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT basquieraanalisa clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT milanesiomartin clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT olmedojulieta clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT caeirogaston clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT basquieraanalisa clinicaltumorlysissyndromeassociatedwithelranatamabinrelapsedmultiplemyelomaacasereport AT milanesiomartin sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT olmedojulieta sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT caeirogaston sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT basquieraanalisa sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT milanesiomartin sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT olmedojulieta sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT caeirogaston sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT basquieraanalisa sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT milanesiomartin sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT olmedojulieta sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT caeirogaston sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT basquieraanalisa sindromedelisistumoralclinicoasociadoaelranatamabenmielomamultiplerecaidoreportedeuncaso AT milanesiomartin sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT olmedojulieta sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT caeirogaston sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT basquieraanalisa sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT milanesiomartin sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT olmedojulieta sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT caeirogaston sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT basquieraanalisa sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT milanesiomartin sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT olmedojulieta sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT caeirogaston sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso AT basquieraanalisa sindromedelisetumoralclinicaassociadaaoelranatamabnomielomamultiplorecidivanterelatodeumcaso |
| first_indexed |
2026-04-27T05:23:56Z |
| last_indexed |
2026-04-27T05:23:56Z |
| _version_ |
1863599979921145856 |
| spelling |
I10-R327-article-492342026-03-30T16:41:22Z Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report Síndrome de lisis tumoral clínico asociado a elranatamab en mieloma múltiple recaído: reporte de un caso Síndrome de lise tumoral clínica associada ao elranatamab no mieloma múltiplo recidivante: relato de um caso Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa Milanesio, Martín Olmedo, Julieta Caeiro, Gastón Basquiera, Ana Lisa multiple myeloma tumor lysis syndrome bispecific antibodies Multiple Myeloma Tumor Lysis Syndrome Immunotherapy Elranatamab mieloma múltiple síndrome de lisis tumoral anticuerpos biespecíficos Mieloma Múltiple Síndrome de lísis tumoral Inmunoterapia Elranatamab mieloma múltiplo síndrome de lise tumoral anticorpos biespecíficos Mieloma Múltiplo Síndrome de Lise Tumoral Imunoterapia Elranatamab Introduction: Multiple Myeloma (MM) is currently an incurable disease, with constant relapses and the need for multiple lines of treatment. Immune therapies, which include bispecific antibodies such as elranatamab, are a new option for the treatment of patients with relapsed/refractory MM (R/R MM), with high effectiveness, but not free of adverse reactions. Tumor lysis syndrome (TLS) is a rare complication of MM treatment and has not been reported after application of elranatamab. Case Presentation: We report the case of a man with R/R MM who presented TLS after application of the first dose of elranatamab. The TLS resolved after supportive measures without subsequent recurrence. Conclusion: TLS is an uncommon complication of MM treatment and could be triggered by bispecific antibodies. Introducción: El Mieloma Múltiple (MM) actualmente es una enfermedad incurable, con recaídas constantes y la necesidad de m´´ultiples líneas de tratamiento. Las terapias inmunes, incluídos los anticuerpos biespecíficos tal como Elranatamab, son una nueva opción para el tratamiento del MM recaído/refractario (MM R/R), con alta efectividad, pero no excento de reacciones adversas. El síndrome de lísis tumoral (SLT) es una rara complicación del tratamiento de MM y no fue reportada luego de la aplicación de Elranatamab. Presentación de caso: Presentamos el caso de un masculino con MM R/R que presentó SLT luego de la primer aplicación de elranatamab. El SLT se resolvió luego de medidas de soporte, sin recurrencia posterior. Conclusión: SLT es una complicación poco común del tratamiento de MM y podría ser secundaria a la aplicación de biespecíficos. Introdução: O mieloma múltiplo (MM) é atualmente uma doença incurável, com recidivas constantes e necessidade de múltiplas linhas de tratamento. As imunoterapias, que incluem anticorpos biespecíficos como o elranatamabe, são uma nova opção para o tratamento de pacientes com MM recidivado/refratário (MM R/R), com alta eficácia, mas não isenta de reações adversas. A síndrome de lise tumoral (SLT) é uma complicação rara do tratamento do MM e não foi relatada após a aplicação de elranatamabe. Apresentação do Caso: Relatamos o caso de um homem com MM R/R que apresentou SLT após a aplicação da primeira dose de elranatamabe. A SLT foi resolvida após medidas de suporte, sem recorrência subsequente. Conclusion: TLS is an uncommon complication of MM treatment and could be triggered by bispecific antibodies. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2026-03-30 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf text/html https://revistas.unc.edu.ar/index.php/med/article/view/49234 10.31053/1853.0605.v83.n1.49234 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 83 No. 1 (2026); e49234 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 83 Núm. 1 (2026); e49234 Revista da Faculdade de Ciências Médicas de Córdoba; v. 83 n. 1 (2026); e49234 1853-0605 0014-6722 10.31053/1853.0605.v83.n1 eng https://revistas.unc.edu.ar/index.php/med/article/view/49234/52766 https://revistas.unc.edu.ar/index.php/med/article/view/49234/52768 Derechos de autor 2026 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0 |